After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. | After striking ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

A two-day meeting of the Advisory Committee on Immunization Practices (ACIP), which was originally scheduled for February but ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

An investigation into the national security implications of pharma imports has been underway for two weeks, the Trump ...

Ever since President Donald Trump nominated Robert F. Kennedy Jr. | In a Friday speech to FDA employees, the HHS secretary ...

Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. | ...

Sanofi has said “deal” to Chrissy Teigen. The model, cookbook author and “Deal or No Deal” banker has signed on as a celebrity spokesperson for Sanofi’s push to encourage people to screen early for ...

Despite President Donald Trump’s threat last week that tariffs on pharmaceuticals will come “very shortly,” the biopharma ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...